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Abstract
Bioisosteric deaza analogues of 6-methyl-9-β-D-ribofuranosylpurine, a hydrophobic analogue of
adenosine, were synthesized and evaluated for antiviral activity. Whereas the 1-deaza and 3-deaza
analogues were essentially inactive in plaque assays of infectivity, a novel 7-deaza-6-methyl-9-β-
D-ribofuranosylpurine analogue, structurally related to the natural product tubercidin, potently
inhibited replication of poliovirus (PV) in HeLa cells (IC50 = 11 nM) and dengue virus (DENV) in
Vero cells (IC50 = 62 nM). Selectivity against PV over cytotoxic effects to HeLa cells was >100-
fold after incubation for 7 h. Mechanistic studies of the 5'-triphosphate of 7-deaza-6-methyl-9-β-
D-ribofuranosylpurine revealed that this compound is an efficient substrate of PV RNA-dependent
RNA polymerase (RdRP) and is incorporated into RNA mimicking both ATP and GTP.
Introduction
Synthetic mimics of adenosine (1) and adenosine triphosphate (ATP) constitute an important
class of therapeutics. A wide variety of kinase inhibitors such as the anticancer drug imatinib
mimic recognition properties of ATP in binding to these enzymes.1 Similarly,
phosphorylated derivatives of antiviral agents such as Adefovir, a sugar-modified analogue
of adenosine, inhibit actions of viral polymerases. Many nucleoside-based mimics of
adenosine are substrates of adenosine kinase and other kinases, and these compounds are
often converted intracellularly into phosphorylated metabolites that exhibit potent biological
activities.2, 3
Although sugar-modified mimics of adenosine have been extensively studied,2, 4, 5 less is
known about how subtle structural modifications to the nucleobase of adenosine collectively
impact both cellular proliferation and antiviral activity. However, minor changes to the
adenosine nucleobase can confer substantial antiproliferative and antiviral effects. For
example, bioisosteric replacement of the exocyclic amino group of 1 with a methyl group
yields 6-methyl-9-β-D-ribofuranosylpurine (2), a potent but non-selective and highly
cytotoxic inhibitor of replication of a number of viruses, including herpes simplex virus-1
*Corresponding author. brpeters@ku.edu; Tel: (785) 864-8156; Fax: (785) 864-8141.
Supporting Information Available: Purity data for synthetic compounds, guanidine resistance assay data, and supporting figures for
NTP incorporation assays. This material is available free of charge via the Internet at http://pubs.acs.org.
NIH Public Access
Author Manuscript
J Med Chem. Author manuscript; available in PMC 2011 November 25.
Published in final edited form as:













(HSV-1) and vaccinia virus. However, the mechanisms of antiviral and cytotoxic action of 2
are poorly understood.6, 7
Numerous other mimics of adenosine bearing deazapurine modifications are known.8 The
natural product tubercidin (3), representing a 7-deazapurine analogue, is a potent
antineoplastic9 and antiviral agent.10 Tubercidin is phosphorylated intracellularly to the
corresponding nucleoside triphosphate,11 is incorporated into DNA and RNA, and exhibits
some polymerase inhibition activity.12, 13 However, this compound is non-selective and too
toxic for clinical use as an antiviral agent.10 Interest in the broad-spectrum antiviral activity
and cytotoxicity of tubercidin has led to a number of studies of nucleobase and sugar-
modified tubercidin analogues.14–17 Olsen and coworkers identified the tubercidin
analogue 7-deaza-2'-C-methyladenosine as an inhibitor of replication of hepatitis C virus
(HCV, IC50 = 0.108 µM) without appreciable cytotoxicity.13 The structurally similar 7-
deaza-2'-C-ethynyladenosine (NITD008) was recently identified as a potent inhibitor of
dengue virus type 2 (DENV2, IC50 = 0.64 µM).18 A series of 7-deazapurine ribonucleosides
with alkyl, aryl, or heteroaryl groups in the 6-position and H, F, or Cl substitution at the 7-
position have also been evaluated in a HCV replicon system.19 However, the decrease in the
replicon reporter signal caused by some of these compounds was attributed to cytostatic
effects. Other deaza adenosine analogues such as 1-deaza and 3-deaza variants exhibit some
antiproliferative activity against certain mammalian cell lines,8 and 3-deaza adenosine is
known to inhibit HIV replication in peripheral blood mononuclear cells.20, 21
We report here the synthesis and biological evaluation of three deazapurine analogues of 2
(compounds 4–6) and related chemical probes (7–9). These hydrophobic mimics of
adenosine were designed to examine the relationship between antiproliferative activity and
antiviral activity against the RNA viruses poliovirus (PV) and dengue virus (DENV) in
vitro. To further investigate the antiviral activity of the novel nucleoside 6, a compound
structurally related to tubercidin (3), we additionally synthesized the 5'-O-methyl analogue 7
as well as the structurally related triphosphate derivatives 8 and 9.
Chemical synthesis
We employed a fusion glycosylation method to synthesize compounds 4 (Scheme 1) and 5.
The known22, 23 nucleobase 7-methyl-3H-imidazo[4,5-b]pyridine (15) was prepared in 5
steps from 2-amino-4-picoline (10) analogous to a previously reported route (Scheme 1).24
Another approach for the preparation of 4 has been published,25 but this method generated a
mixture of isomers at the 7- and 9-positions. To avoid this limitation, we used the fusion
coupling method to exclusively generate the 9- substituted isomer of 16.26 Deprotection of
16 under basic conditions afforded 4 (Scheme 1). The readily prepared nucleobase 4-
chloro-1H-imidazo[4,5-c]pyridine27 was used as an intermediate to yield 3-deaza-6-
methyl-9-β-D-ribofuranosylpurine (5), which was synthesized by known methods.28
The synthesis of the novel nucleoside 7-deaza-6-methyl-9-β-D-ribofuranosylpurine (6)
employed the commercially available nucleoside 17 (Scheme 1).19 Protection as the
peracetate, cross coupling with trimethyl aluminum, and deprotection yielded 6. The 5'-O-
methyl derivative 7 was synthesized by protection of 6 as the acetonide, deprotonation with
sodium hydride, and methylation at the 5'-position to produce intermediate 21. Treatment
with aqueous trifluoroacetic acid afforded 7. The 5'-triphosphate derivative 8, prepared as
previously described,29 and triphosphate 9 were synthesized via the H-phosphonate
monoesters (e.g. 22) using our previously reported one-pot method.29
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Biological evaluation of compounds
As shown in Figure 1 (panel A), compounds 2–7 were evaluated against infectious PV in a
whole-cell assay. HeLa S3 cells were pretreated with 2–7 for 1 h before administration of a
high multiplicity of infection (MOI) of PV. After treatment of cells with PV for 15 min,
fresh media containing 2–7 was added, the infection was allowed to progress for another 6 h,
and the cell-associated viral titer was determined as previously reported.30 Under these
conditions, as listed in Table 1, compounds 2 and 3 inhibited replication of PV (IC50
(2)=1.01 µM; IC50 (3)=0.030 µM). The known compounds 4 and 5 were inactive against PV
at concentrations below 10 µM. However, the novel nucleoside 6 proved to be the most
potent inhibitor of PV replication in this series of compounds (IC50 = 0.011 µM).
Methylation of the 5'-hydroxyl group of 6 to afford 7 eliminated the antiviral effect,
suggesting that like other structurally related compounds, intracellular phosphorylation of 6
is required to generate a biologically active metabolite.
Compounds 2 and 3 are known to be highly cytotoxic or cytostatic to mammalian cells.7, 10
To compare these compounds with analogues 4–7, HeLa S3 cells, the cell line used in the
PV assays, were treated with 2–7 for 7 h, 24 h, and 48 h. Cellular viability was evaluated
with a luciferase assay that quantifies the abundance of ATP present in living cells (Figure
1, panels B–D). These experiments confirmed previous reports7, 10 that although both 2 and
3 are highly cytotoxic, 2 is ~5-fold less toxic than 3 after treatment of cells for 48 h. In
contrast, compounds 4, 5 and 7 showed essentially no cytotoxicity below 10 µM under these
conditions. Interestingly, compound 6 showed a unique bioactivity profile. Unlike
compounds 2 and 3, essentially no cytotoxic effects of 6 to HeLa cells were observed after
treatment for 7 h, the conditions used for the assay against PV. Only after treatment for
longer periods of 24 h or 48 h was the toxicity of 6 evident, and 6 was comparable to 3 only
after 48 h in culture.
The antiviral activities of compounds 2 and 4–7 were further evaluated in a dengue replicon
assay (Figure 2). In this assay, BHK-21 cells stably expressing a luciferase-driven DENV2
replicon were treated with these compounds for 24 h. The cells were subsequently lysed, and
the activity of luciferase was quantified. As listed in Table 1, compound 6 was the most
potent inhibitor (IC50 = 0.88 µM), and compound 2 showed some inhibition of replicon
activity (IC50 = 5.46 µM), but compounds 4, 5, and 7 showed essentially no inhibition below
10 µM.
To further probe the antiviral activity of the novel nucleoside 6, this compound was
evaluated in an infectivity assay with live dengue virus (Figure 2B). Vero cells infected with
DENV2 were treated with 6 for 24 h, and the viral titer was determined by counting viral
plaques present after cell lysis31 and through quantification of DENV2 RNA by real time
PCR.32 In these assays, compound 6 was a highly potent inhibitor of DENV2 replication
(plaque assay IC50 (6) = 0.062 µM; real time PCR IC50 (6) = 0.039 µM). To examine
whether the antiviral mechanism of action of 6 or 2 might involve lethal viral mutagenesis,
these compounds were compared with ribavirin in a guanidine resistance assay.30 Ribavirin,
a clinically employed antiviral drug, becomes phosphorylated intracellularly, mimics purine
ribonucleotides, and becomes misincorporated into the genome of RNA viruses, resulting in
loss of function due to error catastrophe.30, 33 However, compared to ribavirin, neither 6
nor 2 increased the frequency of viral mutagenesis (Supporting information, Table S1),
indicating that the antiviral activity of these compounds against PV is mechanistically
distinct from ribavirin.
Intracellular adenosine kinase is known to phosphorylate a wide variety of base-modified
mimics of adenosine, including tubercidin (3).34, 35 Following this rate-limiting
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phosphorylation step, monophosphorylated mimics of adenosine are generally converted to
triphosphates by other nucleotide kinases. Because 2, 3, 6 and adenosine are highly
structurally similar, these compounds are very likely to be converted to triphosphate
metabolites that function as the biologically active species in cells. Consistent with this idea,
methylation of the 5'-alcohol of 6 to yield 7 was found to reduce biological activity by over
1000-fold (Table 1).
To further examine the biological properties of triphosphate derivatives of 2 and 6, we
synthesized 5'-triphosphates 8 and 9. Using a previously reported primer-extension assay,36
we studied the in vitro incorporation of these compounds into RNA by poliovirus RNA-
dependent RNA polymerase (PV RdRP, 3Dpol). In this assay, both 8 and 9 became
incorporated opposite uracil and cytosine, but exhibit almost no incorporation opposite
adenine and guanine (Figure 3). As expected for compounds structurally related to ATP, the
incorporation efficiency of both 8 and 9 across from uracil was comparable to natural ATP
on this time scale. Compared with GTP, incorporation opposite cytosine after reaction for 10
min was ~40% for 8 and ~60% for 9, illustrating the importance of the exocyclic amino
group of ATP for discrimination of the complementary nucleobase in RNA by PV RdRP.
To assess the efficiency of 8 and 9 as substrates for RNA extension by PV RdRP when
templated by U, pre-steady state kinetics of incorporation were measured. Values for kpol,
the maximal rate constant for single nucleotide addition, Kd,app, the kinetically-measured
binding constant for 8 or 9 to the PV RdRP-RNA primer/template complex, and kpol/Kd,app,
a measure of substrate efficiency, are summarized in Table 2 (data shown in Figures S8 and
S9). Also shown are previously published kinetic values for complementary natural ATP
and the purine mimic ribavirin triphosphate (RTP). Efficiencies of 8 and 9 are only ten-fold
lower than natural ATP, indicating that these analogues are robust substrates for PV RdRP
when templated by U. For comparison, the efficiency of RTP is approximately three orders
magnitude lower than 8 or 9. In contrast to the robust incorporation of 8 and 9 by PV RdRP
opposite U, incorporation opposite C is extremely slow (Figure S10).
Additionally, although other antiviral nucleosides are known to function by causing
termination of the growing RNA chain,37 both 8 and 9 were capable of extending RNA
oligomers to the +4 position (Supporting information, Figure S11), indicating that neither of
these compounds functions as a RNA chain terminator.
To investigate the effects of triphosphates 8 and 9 on PV RdRP-RNA primer/template
complexes and inhibition of RdRP, these compounds were assessed in steady state
incorporation assays (Figure 4). The concentration of products of incorporation of 8, 9, ATP,
and GTP templated by uracil or cytosine was plotted versus time, and the calculated kcat
(quotient of slope/y-intercept from linear fits to data points), which is related to the
dissociation rate constant of RdRP from RNA primer/template, was compared (Figure 4).
These experiments revealed that both 8 and 9 destabilize PV RdRP-RNA primer/template
complexes, as evidenced by increases in kcat compared with natural correct nucleotides
(ATP opposite U; GTP opposite C). It should be noted that the concentrations of 8 and 9
with template U approached saturation, yielding true estimates of kcat. Due to the extremely
slow incorporation opposite C, whether or not saturation of 8 and 9 with template C was
approached was not determined. Nevertheless, the slopes of the time courses of steady state
incorporation of both 8 and 9 were constant over time, indicating that neither 8 nor 9 inhibit
PV RdRP.
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Examined collectively, the kinetics of incorporation of triphosphates 8 and 9 into RNA, the
known structure-activity relationships governing phosphorylation of ATP, tubercidin, and
related compounds, and the lack of biological activity of control compound 7 suggest that
triphosphate 9 represents the active antiviral metabolite of compound 6. This compound (9)
functions as a robust substrate of PV RdRP, and it likely engenders antiviral effects not by
inhibiting the viral polymerase or by chain termination of viral RNA but through a
downstream mechanism that may involve RNA-RNA or protein-RNA interactions, or
possible effects on host enzymes essential for viral replication. Once incorporated into RNA,
the product of 9 may alternatively function as a defective templating base in duplex
synthesis because of the missing C6 amino group involved in Watson-Crick base pairing and
the missing nitrogen atom at the 7-position. This RNA modification may lead to slow or
defective synthesis of complementary RNA, or stalling or dissociation of PV RdRP when an
analogue-templated site is encountered, or possibly result in other effects that block
successful replication of the viral genome.
Interestingly, the cytotoxicity profiles of compounds 2–7 differ substantially. The
cytotoxicity of tubercidin (3) is thought to derive from suppression of a number of cellular
processes including mitochondrial respiration, de novo purine synthesis, processing of
rRNA, tRNA methylation and protein and RNA synthesis.10 Whereas 2 and 3 show
pronounced effects on proliferation of HeLa cells after treatment for only 7 h, compounds 4–
7 show little cytotoxicity during that time period. Moreover, significant cytotoxic effects of
6 are evident only after 24 to 48 h. These results suggest that subtle modifications to the
adenine heterocycle show promise for separation of antiviral from cytotoxic effects on host
cells. In addition, robust use of 8 and 9 as substrates by PV RdRP suggests the possibility
that cytotoxicity may result from off-target effects on human RNA polymerases, including
human mitochondrial RNA polymerase.
Conclusion
A novel 7-deaza derivative of 6-methyl-9-β-D-ribofuranosylpurine (6) was synthesized. This
compound (6) exhibits highly potent activity against PV and DENV2 in cell culture assays
and possesses an improved cytotoxicity profile compared to 6-methyl-9-β-D-
ribofuranosylpurine (2) and tubercidin (3). Studies of the putative triphosphate metabolites
of 2 and 6 revealed that these compounds (8, 9) do not inhibit the viral polymerase, do not
serve as RNA chain terminators, and are not lethal mutagens, but rather are robust substrates
for PV RdRP. These results suggest antiviral mechanisms of action that involve downstream
effects on RNA-RNA interactions, RNA-protein interactions, or perturbation of endogenous
targets in host cells.
Experimental section
General
Chemical reagents and solvents were obtained from Acros, Aldrich, TCI America or Fisher
Scientific without further purification unless otherwise noted. Anhydrous solvents were
obtained after passage through a drying column of a solvent purification system from
GlassContour (Laguna Beach, CA). Reactions were performed under an atmosphere of dry
nitrogen. Reactions were monitored by analytical thin-layer chromatography on plates
coated with 0.25 mm silica gel 60 F254 (EMD Chemicals). TLC plates were visualized by
UV irradiation (254 nm) or stained with 20% sulfuric acid in ethanol. Nuclear magnetic
resonance (NMR) spectroscopy employed a Bruker DRX 400 spectrometer. NMR peaks are
reported as parts per million (ppm) referenced to internal CHCl3, MeOH or H2O peaks.
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Mass spectral data was obtained from The University of Kansas Mass Spectrometry Facility.
Melting points were determined on a Thomas Hoover apparatus and are uncorrected.
Column chromatography employed silica gel (ICN SiliTech, 32–63 µm) or Sephadex LH-20
(GE Healthcare, column dimensions: 2.5 cm × 40 cm). Purification by preparative HPLC
employed an Agilent 1100 series instrument equipped with an Atlantis C18 preparative
column (19 × 150 mm, 5 µm; Waters Corporation). The HPLC flow rate was maintained at
25 mL/min for the duration of the run. Determination of purity of compounds 2 and 4–7 by
analytical HPLC used a PRP-1 (polystyrene-divinylbenzene) reverse-phase column (4.1 ×
250 mm, 7 µm; Hamilton) and a gradient of 1% to 99% CH3CN (containing 0.1% TFA) in
nanopure water (containing 0.1% TFA, 0 to 30 min) followed by 99% CH3CN (containing
0.1% TFA) from 30–40 min at a flow rate of 0.8 mL/min. Analysis of purity of compounds
8–9 by HPLC used an Aquasil column (4.6 × 250 mm, 5 µm; Thermoelectron Corporation)
at a flow rate of 1.0 mL/min with a gradient of 1% to 50% CH3CN in aqueous KH2PO4 (100
mM, pH = 6.0) over 30 min followed by 50% CH3CN in aqueous KH2PO4 from 30–40 min.
6-Methyl-9-β-D-ribofuranosylpurine (2)7 and 6-methyl-9-β-D-ribofuranosylpurine 5'-
triphosphate (8)29 were prepared as previously reported. All compounds studied in
biological assays were of •95% purity as evidenced by analytical HPLC.
5-Bromo-2-amino-4-methylpyridine (11)
This known compound was prepared by modification of a previously reported38 route. 2-
Amino-4-methylpyridine (Aldrich, 10, 2.49 g, 23.0 mmol) in CH2Cl2 (30 mL) was cooled to
−45 °C with dry ice in a bath of CH3CN. 1,3-Dibromo-5,5-dimethylhydantoin (6.58 g, 23.0
mmol) was added and the mixture was stirred at −45 °C for 30 min. Saturated aqueous
NaHCO3 (40 mL) was added, the mixture was allowed to warm to room temperature (22
°C), and CH2Cl2 (100 mL) was added. The organic layer was separated, dried over
anhydrous sodium sulfate and evaporated. The resulting residue was recrystallized from
EtOAc to yield 11 (3.53 g, 82%) as a pale brown solid. 1H NMR (400 MHz, CDCl3) δ 8.10
(s, 1H), 6.42 (s, 1H), 4.37 (s, 2H), 2.29 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 149.2 (×3),
110.3 (×2), 22.3.
5-Bromo-4-methyl-3-nitropyridin-2-amine (12)
This known compound was prepared by modification of a previously reported39 route. 5-
Bromo-2-amino-4-methylpyridine (11, 2.43 g, 13.0 mmol) was dissolved in concentrated
H2SO4 (20 mL), and the solution was cooled to −10 °C with a bath of ice and NaCl. HNO3
(14 mL) was added dropwise, the reaction mixture was stirred for 30 min and allowed to
warm to room temperature (22 °C). The mixture was poured into an ice / water mixture (50
mL), and the pH was adjusted to 3 by addition of concentrated aqueous ammonium
hydroxide (22%). A light yellow precipitate was collected by filtration, washed with water
and dried in vacuo. The resulting solid was dissolved in H2SO4 (20 mL), and the mixture
was stirred at room temperature (22 °C) for 2 h. The reaction solution was poured onto ice
and neutralized with aqueous ammonium hydroxide (22%). After extraction with CH2Cl2 (3
× 70 mL), the combined organic layers were dried over anhydrous sodium sulfate and
evaporated. The crude product was recrystallized from CH2Cl2 to afford 12 (1.93 g, 64%) as
a yellowish brown solid. 1H NMR (400 MHz, CDCl3) d 8.30 (s, 1H), 5.88 (s, 2H), 2.55 (s,
3H); 13C NMR (100 MHz, CDCl3) d 153.4 (×2), 151.5, 144.1, 111.8, 20.4.
5-Bromo-4-methylpyridine-2,3-diamine (13)
This known compound was prepared by modification of a previously reported40 route.
SnCl2 (6.23 g, 27.6 mmol) was dissolved in concentrated aqueous hydrochloric acid, and the
mixture was cooled to 0 °C. 5-Bromo-4-methyl-3-nitropyridin-2-amine (12, 1.60 g, 6.90
mmol) was added to this solution in four portions, the reaction mixture was warmed to room
temperature (22 °C) and placed in an oil bath maintained at 100 °C for 1 h. After cooling,
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the solution was adjusted to pH = 11 with aqueous NaOH solution (40%). The precipitate
was collected by filtration, washed with water, and the crude product was further purified by
flash chromatography (eluent: hexane, EtOAc, 1:1) to yield 13 (0.989 g, 66%) as a light
brown solid. 1H NMR (400 MHz, CD3OD) d 7.49 (s, 1H), 2.34 (s, 3H); 13C NMR (100
MHz, CD3OD) d 147.3, 135.4, 127.6, 120.1, 111.8, 15.2.
6-Bromo-7-methyl-3H-imidazo[4,5-b]pyridine (14)
This known compound was prepared by modification of a previously reported40 route. 5-
Bromo-4-methylpyridine-2,3-diamine (13, 0.695 g, 3.20 mmol) was dissolved in formic acid
(5 mL) and heated to reflux for 1 h. The formic acid was removed in vacuo, and the residue
was recrystallized from methanol to give 14 (250 mg) as an orange solid. Chromatographic
purification of the mother liquor yielded another 220 mg of the product (yield: 69%). 1H
NMR (400 MHz, CD3OD) d 8.43 (s, 1H), 8.35 (s, 1H), 2.68 (s, 3H); 13C NMR (100 MHz,
CD3OD) d 145.0 (×6), 17.1.
7-Methyl-3H-imidazo[4,5-b]pyridine (15)
6-Bromo-7-methyl-3H-imidazo[4,5-b]pyridine (14, 403 mg, 1.90 mmol) in aqueous NaOH
(1%, 20 mL) containing PtO2 (29.5 mg, 0.130 mmol) and palladium on carbon (10%, 298
mg, 0.280 mmol) was hydrogenated in a Parr apparatus for 30 min at 50 psi. The catalyst
was removed by filtration through celite, and the filtrate was neutralized by dropwise
addition of aqueous hydrochloric acid (2 M). After extraction with CH2Cl2 (3 × 50 mL), the
organic layers were combined, dried over anhydrous sodium sulfate and evaporated in
vacuo. The crude product was recrystallized from CH2Cl2 to afford 15 (148 mg, 59%) as a
white solid. 1H NMR (400 MHz, CD3OD) d 8.34 (s, 1H), 8.22 (d, 1H, J = 5.0 Hz), 7.12 (d,




A mixture of 7-methyl-3H-imidazo[4,5-b]pyridine (15, 70.2 mg, 0.520 mmol), β-D-
ribofuranose 1,2,3,5-tetraacetate (Aldrich, 318 mg, 1.00 mmol), and p-toluenesulfonic acid
(19.0 mg, 0.10 mmol) was heated to 170 °C under reduced pressure (12–15 mm Hg) with
stirring for 20 min. The resulting solid was neutralized with saturated aqueous NaHCO3 and
extracted with CH2Cl2 (4 × 40 mL). The combined organic layers were dried over
anhydrous sodium sulfate, and removed in vacuo to afford a residue that was purified by
flash column chromatography (eluent: hexane, EtOAc, 4:1) to yield 16 (101 mg, 49%) as a
white foam. mp 53–55 °C; 1H NMR (400 MHz, CDCl3) d 8.27 (d, 1H, J = 4.9 Hz), 8.17 (s,
1H), 7.09 (d, 1H, J = 4.9 Hz), 6.30 (d, 1H, J1', 2' = 5.3 Hz), 6.04 (dd, 1H, J2', 1' = 5.3 Hz,
J2', 3' = 5.4 Hz), 5.74 (dd, 1H, J3', 2' = 5.4 Hz, J3', 4' = 2.8 Hz), 4.49-4.37 (m, 3H), 2.68 (s,
3H), 2.15 (s, 3H), 2.13 (s, 3H), 2.08 (s, 3H); 13C NMR (100 MHz, CDCl3) d 170.4, 169.6,
169.4, 145.9, 144.6, 141.2, 140.1, 135.8, 120.1, 86.3, 80.0, 73.0, 70.8, 63.2, 20.8, 20.6, 20.4,
16.2; IR (film) l max 3412, 2912, 2846, 1748, 1608, 1498, 1432, 1372, 1228, 1092, 1045
cm−1; HRMS (ESI+) m/z 392.1444 (M+, C18H22N3O7 requires 392.1458).
4-Chloro-7-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine (7-deaza-6-
chloro-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)purine, 18)
A solution of 17 (prepared as previously reported19 or from TRC Biomedical Research
Chemicals, 300 mg, 1.00 mmol) in dry pyridine (5 mL) was cooled to 4 °C, and Ac2O
(0.501 mL, 5.30 mmol) was added dropwise. The mixture was allowed to warm to room
temperature (22 °C) and continuously stirred for 4 h. The reaction solution was cooled to 4
°C, and H2O (10 mL) was added to quench the reaction. The reaction was extracted with
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CH2Cl2 (4 × 40 mL), and the combined organic layers were washed with H2O (2 × 30 mL),
dried over anhydrous sodium sulfate, evaporated to dryness, and the product was purified by
flash chromatography (eluent: hexane, EtOAc, 3:1) to yield a white foam (18, 344 mg,
84%). 1H NMR (400 MHz, CDCl3) d 8.67 (s, 1H), 7.43 (d, 1H, J = 3.8 Hz), 6.70 (d, 1H, J =
3.8 Hz), 6.46 (d, 1H, J1', 2' = 6.0 Hz), 5.76 (dd, 1H, J2', 1' = 6.0 Hz, J2', 3' = 5.8 Hz), 5.57 (dd,
1H, J3', 2' = 5.8 Hz, J3', 4' = 4.4 Hz), 4.44-4.34 (m, 3H), 2.16 (s, 3H), 2.15 (s, 3H), 2.05 (s,
3H); 13C NMR (100 MHz, CDCl3) d 170.3, 169.7, 169.4, 152.6, 151.5, 151.2, 126.2, 118.5,
101.5, 85.9, 79.9, 73.1, 70.7, 63.3, 20.8, 20.6, 20.4.
4-Methyl-7-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine (7-deaza-6-
methyl-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)purine, 19)
A mixture of 18 (285 mg, 0.690 mmol), Pd(PPh3)4 (160 mg, 0.140 mmol) and trimethyl
aluminum (2 M solution in hexanes, 0.690 mL, 1.380 mmol) in THF (10 mL) was heated to
reflux for 7 h. Saturated aqueous NH4Cl was added slowly to quench the reaction, and the
volatile fraction was removed in vacuo. After extraction with EtOAc (3 × 50 mL), the
organic layers were combined, washed with saturated aqueous sodium chloride solution,
dried over anhydrous sodium sulfate and evaporated to a colorless oil, which was purified by
flash chromatography (eluent: hexane, EtOAc, 1:3) to give 19 (165 mg, 61%) as a white
foam. mp 48–49 °C; 1H NMR (400 MHz, CDCl3) d 8.80 (s, 1H), 8.34 (d, 1H, J = 3.8 Hz),
6.66 (d, 1H, J = 3.8 Hz), 6.52 (d, 1H, J1', 2' = 6.0 Hz), 5.79 (dd, 1H, J2', 1' = 6.0 Hz, J2', 3' =
5.8 Hz), 5.60 (dd, 1H, J3', 2' = 5.8 Hz, J3', 4' = 3.9 Hz), 4.44-4.36 (m, 3H), 2.75 (s, 3H), 2.18
(s, 3H), 2.17 (s, 3H), 2.06 (s, 3H); 13C NMR (100 MHz, CDCl3) d 170.4, 169.8, 169.5,
159.9, 151.7, 150.9, 124.5, 118.7, 101.5, 85.3, 79.6, 73.0, 70.8, 63.4, 21.6, 20.8, 20.6, 20.4;
IR (film) l max 3434, 3132, 2928, 2846, 1748, 1684, 1586, 1514, 1429, 1374, 1229, 1095,
1042 cm−1; HRMS (ESI+) m/z 392.1443 (M+, C18H22N3O7 requires 392.1458).
General procedure for deprotection of compounds 16 and 19 (0.220 mmol scale) to yield 4
and 6
These compounds were treated with ammonia in methanol (7 N, 5 mL), and stirred at room
temperature (22 °C) for 4 h. The solvent was removed in vacuo and the residue was purified
by flash column chromatography (eluent: CH2Cl2, MeOH, 9:1). The resulting solid was
further purified by recrystallization from methanol.
7-Methyl-3-β-D-ribofuranosyl-3H-imidazo[4,5-b]pyridine (1-deaza-6-methyl-9-β-D-
ribofuranosylpurine, 4)
After deprotection of 16, compound 4 was obtained as a white solid (52.5 mg, 90%). mp
198–200 °C. 1H NMR (400 MHz, CD3OD) d 8.55 (s, 1H), 8.22 (d, 1H, J = 5.0 Hz), 7.21 (d,
1H, J = 5.0 Hz), 6.06 (d, 1H, J1', 2' = 6.4 Hz), 4.82 (dd, 1H, J2', 1' = 6.4 Hz, J2', 3' = 5.2 Hz),
4.34 (dd, 1H, J3', 2' = 5.2 Hz, J3', 4' = 2.6 Hz), 4.19 (ddd, 1H, J4', 3' = 2.6 Hz, J4', 5' = 2.4, 2.6
Hz), 3.89 (dd, 1H, Jgem = 12.5 Hz, J5'a, 4' = 2.4 Hz), 3.76 (dd, 1H, Jgem = 12.5 Hz, J5'b, 4' =
2.6 Hz), 2.66 (s, 3H); 13C NMR (100 MHz, CD3OD) d 145.1, 143.5, 143.4, 140.4, 135.6,
119.7, 90.0, 73.7, 71.3, 62.1, 20.6, 14.9; IR (film) l max 3271, 2912, 2852, 1610, 1501,
1206, 1081 cm−1; HRMS (ESI+) m/z 266.1138 (M+, C12H16N3O4 requires 266.1141).
4-Methyl-7-β-D-ribofuranosylpyrrolo[2,3-d]pyrimidine (7-deaza-6-methyl-9-β-D-
ribofuranosylpurine, 6)
After deprotection of 19, compound 6 was obtained as a white solid (52.7 mg, 90%). mp
175–176 °C; 1H NMR (400 MHz, CD3OD) d 8.61 (s, 1H), 7.70 (d, 1H, J = 3.8 Hz), 6.74 (d,
1H, J = 3.8 Hz), 6.20 (d, 1H, J1', 2' = 6.2 Hz), 4.61 (dd, 1H, J2', 1' = 6.2 Hz, J2', 3' = 5.5 Hz),
4.29 (dd, 1H, J3', 2' = 5.5 Hz, J3', 4' = 3.3 Hz), 4.10 (ddd, 1H, J4', 3' = 3.3 Hz, J4', 5' = 3.0, 3.3
Hz), 3.84 (dd, 1H, Jgem = 12.2 Hz, J5'a, 4' = 3.0 Hz), 3.74 (dd, 1H, Jgem = 12.2 Hz, J5'b, 4' =
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3.3 Hz), 2.72 (s, 3H); 13C NMR (100 MHz, DMSO-d6) d 175.0, 159.4, 149.8, 127.3, 119.0,
100.0, 89.0, 85.6, 74.3, 71.0, 62.0, 20.7; IR (film) l max 3293, 2923, 1594, 1569, 1514,




Compound 6 (450 mg, 1.70 mmol) was dissolved in acetone (5 mL). 1,2-Dimethoxy
propane (5 mL) and p-toluenesulfonic acid (442 mg, 4.20 mmol) were added. The mixture
was stirred at room temperature (22 °C) for 20 min. MeOH (20 mL) was added to dilute the
solution, and Amberlite IRA-400 (OH) resin (from Supelco) was used to modify the pH
value to 7. The resin was removed by filtration and washed with MeOH (30 mL), and the
filtrate was evaporated in vacuo. The product was purified by flash chromatography (eluent:
CH2Cl2, MeOH, 25:1) to afford 404 mg of 20 as a white foam (78%). mp 67–68 °C; 1H
NMR (400 MHz, CD3OD) d 8.64 (s, 1H), 7.69 (d, 1H, J = 3.8 Hz), 6.74 (d, 1H, J = 3.8 Hz),
6.34 (d, 1H, J1', 2' = 3.6 Hz), 5.21 (dd, 1H, J2', 1' = 3.6 Hz, J2', 3' = 6.3 Hz), 5.03 (dd, 1H,
J3', 2' = 6.3 Hz, J3', 4' = 2.9 Hz), 4.30 (dd, 1H, J4', 3' = 2.9 Hz, J4', 5' = 3.9 Hz), 3.78 (dd, 1H,
Jgem = 12.0 Hz, J5'a, 4' = 3.9 Hz), 3.72 (dd, 1H, Jgem = 12.0 Hz, J5'b, 4' = 3.9 Hz), 2.72 (s,
3H), 1.63 (s, 3H), 1.39 (s, 3H); 13C NMR (100 MHz, CD3OD) d 159.4, 150.1, 149.9, 127.3,
118.7, 114.0, 100.2, 90.6, 85.8, 84.0, 81.3, 62.0, 26.2, 24.2, 19.5; IR (film) l max 3275,
2984, 2928, 1676, 1588, 1566, 1427, 1374, 1210, 1073 cm−1; HRMS (ESI+) m/z 306.1443
(M+, C15H20N3O4 requires 306.1454).
4-Methyl-7-β-D-ribofuranosylpyrrolo[2,3-d]pyrimidine 5'-H-phosphonate (7-deaza-6-
methyl-9-β-D-ribofuranosylpurine 5'-H-phosphonate, 22)
To a solution of phosphorus trichloride (0.500 mL, 5.73 mmol) in anhydrous CH2Cl2 at −20
°C, 4-methyl-7-(2',3'-O-isopropylidene-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine (20,
174 mg, 0.570 mmol) was added and the solution was stirred for 1 h at −20 °C. The reaction
was warmed to room temperature (22 °C) and stirred for 4 h. The solvent was evaporated in
vacuo and the residue was treated with aqueous TFA (2 mL, 30%) for 20 min. The reaction
mixture was concentrated in vacuo, the crude product was dissolved in aqueous
triethylammonium bicarbonate (TEAB) buffer (1 mL, 10 mM, pH = 8), and the product was
purified by Sephadex LH-20 column (2.5 cm × 40 cm). Elution with 10 mM aqueous TEAB
buffer and lyophilization yielded 22 as the triethylammonium salt, a colorless glassy solid
(139 mg, 62%). 1H NMR (400 MHz, D2O) d 8.37 (s, 1H), 7.55 (d, 1H, J = 3.8 Hz), 6.62 (d,
1H, J = 3.8 Hz), 6.61(d, 1H, JP, H = 638 Hz), 6.19 (d, 1H, J1', 2' = 6.4 Hz), 4.57 (dd, 1H,
J2', 1' = 6.4 Hz, J2', 3' = 5.6 Hz), 4.36 (dd, 1H, J3', 2' = 5.6 Hz, J3', 4' = 3.2 Hz), 4.22 (ddd, 1H,
J4', 3' = 3.2 Hz, J4', 5' = 1.5, 1.2 Hz), 3.98 (dd, 1H, Jgem = 2.8 Hz, J5'a, 4' = 1.5 Hz), 3.97 (dd,
1H, Jgem = 2.8 Hz, J5'b, 4' = 1.2 Hz), 3.05 (q, 6H, J = 7.4 Hz, N(CH2CH3)3), 2.46 (s, 3H),
1.13 (t, 9H, J = 7.4 Hz, N(CH2CH3)3); 13C NMR (100 MHz, D2O) d 154.7, 150.3, 143.7,
130.3, 118.4, 104.1, 87.1, 84.0 (Jc, p = 8 Hz), 74.3, 70.6, 63.1 (Jc, p = 4 Hz), 46.6, 16.7,




Prior to the reaction, tris(tetra-n-butylammonium) hydrogen pyrophosphate (prepared as
previously described,41 dried over P2O5, and stored at −20 °C, 116 mg, 0.13 mmol) and
compound 25 (55.0 mg, 0.130 mmol) were dried overnight under vacuum at room
temperature (22 °C) in two separate round bottom flasks. Anhydrous DMF (1.5 mL) and
pyridine (250 µL, 3.00 mmol) were added to the round bottom flask containing 22. After the
solid was dissolved, TMSCl (132 µL, 1.04 mmol) was added by gas tight microsyringe.
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After 5 min, a solution of I2 in DMF (0.2 M, 910 µL) was added dropwise. The mixture was
stirred for 5 min at 22 °C before a solution of tris(tetra-n-butylammonium) hydrogen
pyrophosphate in DMF (0.5 mL) was added. The reaction mixture was stirred at room
temperature (22 °C) for 30 min and concentrated in vacuo. The residue was dissolved in
cold deionized water (1 mL) by sonication for 1 min. The precipitated iodine was removed
by filtration through a small plug of cotton inserted in the bottom of a 12 cm glass Pasteur
pipet. The product was purified by Sephadex LH-20 column with ice-cold aqueous TEAB
buffer (10 mM, pH = 8) as the eluent. The fractions containing the triphosphate were
identified by mass spectrometry, combined and lyophilized to yield the crude product, which
was further purified by preparative reverse-phase HPLC with a linear gradient of 0% to 10%
CH3CN in aqueous TEAB buffer (10 mM, pH = 7.5, adjusted with acetic acid) over 30 min
(Retention time = 10.8 to 12.0 min). Repeated lyophilization and resuspension in deionized
water (3 × 3 mL) yielded 9 as the triethylammonium salt, a colorless glassy solid. 1H NMR
(400 MHz, D2O) d 8.56 (s, 1H), 7.76 (d, 1H, J = 3.8 Hz), 6.82 (d, 1H, J = 3.8 Hz), 6.30 (d,
1H, J1', 2' = 7.0 Hz), 4.65 (dd, 1H, J2', 1' = 7.0 Hz, J2', 3' = 4.7 Hz), 4.48 (dd, 1H, J3', 2' = 4.7
Hz, J3', 4' = 2.8 Hz), 4.27-4.26 (m, 1H), 4.18-4.04 (m, 2H), 3.08 (q, 18H, J = 7.3 Hz), 2.65 (s,
3H), 1.15 (t, 27H, J = 7.3 Hz); 31P NMR (162 MHz, D2O) d −10.2 (d, Jp, p = 19.9 Hz),





mg, 0.144 mmol) was dissolved in CH3CN (1 mL), and cooled to 4 °C. NaH (11.6 mg,
0.288 mmol) was added, and the resulting suspension was stirred at 4 °C for 0.5 h before
adding MeI (0.180 mL, 0.288 mmol). The mixture was stirred at room temperature (22 °C)
for 2 h. MeOH (3 mL) was added to quench excess NaH. After removal of solvent in vacuo,
the crude product was purified by flash chromatography (eluent: hexane, EtOAc, 1:1) to
afford 40.0 mg of a colorless oil (86%). 1H NMR (400 MHz, CDCl3) δ 8.78 (s, 1H), 7.38 (d,
1H, J = 3.7 Hz), 6.58 (d, 1H, J = 3.7 Hz), 6.38 (d, 1H, J1', 2' = 2.9 Hz), 5.21 (dd, 1H, J2', 1' =
2.9 Hz, J2', 3', = 6.4 Hz), 5.00 (dd, 1H, J3', 2' = 6.4 Hz, J3', 4' = 3.4 Hz), 4.39 (ddd, 1H, J4', 3' =
3.4 Hz, J4', 5' = 3.9, 4.8 Hz), 3.63 (dd, 1H, Jgem = 10.3 Hz, J5'a, 4' = 3.9 Hz), 3.59 (dd, 1H,
Jgem = 10.3 Hz, J5'b, 4' = 4.8 Hz), 3.39 (s, 3H), 2.73 (s, 3H), 1.66 (s, 3H), 1.39 (s, 3H); 13C
NMR (100 MHz, CDCl3) δ 159.5, 151.5, 150.3, 125.9, 118.6, 114.4, 100.4, 90.4, 84.7, 84.5,
81.5, 72.9, 59.3, 27.3, 25.4, 21.5; IR (film) λ max 2984, 2928, 1586, 1512, 1460, 1374,
1347, 1215, 1092 cm−1; HRMS (ESI+) m/z 320.1595 (M+, C16H22N3O4 requires 320.1610).
4-Methyl-7-(5'-O-methyl-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine (7-deaza-6-methyl-9-(5'-
O-methyl-β-D-ribofuranosyl)purine, 7)
Compound 21 (40.0 mg, 0.125 mmol) was treated with aqueous TFA (70%, 1 mL), and
stirred at room temperature (22 °C) for 15 min. The solvent was removed in vacuo, and the
residue was purified by flash chromatography (eluent: CH2Cl2, MeOH, 20:1) to yield 30.4
mg of 7 as a white foam (87%). mp 63–65 °C; 1H NMR (400 MHz, CD3OD) δ 8.89 (s, 1H),
8.01 (d, 1H, J = 3.9 Hz), 7.06 (d, 1H, J = 3.9 Hz), 6.42 (d, 1H, J1', 2' = 5.6 Hz), 4.48 (dd, 1H,
J2', 1' = 5.6 Hz, J2', 3' = 5.3 Hz), 4.29 (dd, 1H, J3', 2' = 5.3 Hz, J3', 4' = 3.6 Hz), 4.19 (ddd, 1H,
J4', 3' = 3.6 Hz, J4', 5' = 3.0, 3.4 Hz), 3.71 (dd, 1H, Jgem = 10.8 Hz, J5'a, 4' = 3.0 Hz), 3.63 (dd,
1H, Jgem = 10.8 Hz, J5'b, 4' = 3.4 Hz), 3.45 (s, 3H), 2.91 (s, 3H); 13C NMR (100 MHz,
CD3OD) δ 155.3, 150.5, 145.3, 129.5, 118.1, 102.3, 88.0, 84.3, 75.3, 72.2, 71.2, 58.2, 16.8;
IR (film) λ max 3354, 3110, 2923, 2890, 2066, 1682, 1643, 1602, 1515, 1463, 1201, 1131
cm−1; HRMS (ESI+) m/z 280.1285 (M+, C13H18N3O4 requires 280.1297).
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HeLa S3 cells (ATCC# CCL-2.2) were maintained in DMEM/F-12 media supplemented
with 2% dialyzed fetal bovine serum and 1% penicillin/streptomycin (1 ×, Invitrogen). HeLa
S3 cells (4 × 103) in 100 µL media were loaded on a 96-well plates 24 h before use. Cells
were incubated with ribonucleosides at various concentrations for 7 h, 24 h and 48 h
respectively at 37 °C. All wells were adjusted to a final concentration of 0.1% DMSO.
Media was removed and cells were washed with PBS (100 µL). 100 µL media, 75 µL PBS
and 25 µL CellTiter-Glo reagent (Promega) were added to each well, and the 96-well plate
was shaken on a titer plate shaker for 2 min to detach the cells. The cell suspension (200 µL)
was transferred to an opaque 96-well plate according to the Promega protocol provided with
the reagent. After incubation at room temperature (22 °C) for 10 min, the luminescence of
the samples was measured with a Packard Fusion microtiterplate reader. The IC50 values
were calculated by with a nonlinear four-parameter curve fit (GraphPad Prism 5.0) of
luciferase activity vs. concentration of nucleoside.
Antiviral assay against poliovirus (PV)
HeLa S3 cells (1 × 105) were plated 1 day prior to treatment in a 24-well plate. Cells were
pretreated with different concentrations of nucleosides in fresh media containing 0.1%
DMSO. After 1 h incubation at 37 °C, media was removed and cells were infected with PV
(1 × 106 PFU) in PBS (100 µL). Plates were incubated for 15 min at room temperature (22
°C), PBS was removed by aspiration, and fresh media containing the specified amount of
nucleoside was added. The infection was allowed to proceed at 37 °C for 6 h. Cells were
washed with PBS and collected by treatment with trypsin. Cells were pelleted by
centrifugation, resuspended in PBS (500 µL), and subjected to 3 freeze-thaw cycles. Cell
debris was removed by centrifugation and the supernatant containing the cell-associated
virus was saved. Viral titer was determined by applying serial dilutions of supernatant to
HeLa S3 monolayers (plated in 6-well plates 1 day before at 5 × 105 cells/well) and
overlaying with growth media containing low melting point agarose (1%). Plates were
incubated for 2 days at 37 °C. The agarose was removed and plaques were visualized by
staining with crystal violet (1%) in aqueous ethanol (20%). The IC50 values were calculated
by with a nonlinear four-parameter curve fit (GraphPad Prism 5.0) of viral titer vs.
concentration of nucleoside.
Antiviral assays against dengue (DENV2)
DENV2 replicon assay—BHK-21 cells stably expressing the DENV2 replicon were
thawed and cultured in DMEM/F-12 media supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin (1×, Invitrogen). Cells (6 × 104) were seeded in a 48-well plate
24 h before use. Nucleosides at different concentrations in media containing 1% DMSO
were used to treat cells for 24 h. Cells were washed with PBS once and lysed by adding lysis
buffer (Promega, 60 µL/well) and passing the lysate through 27-gauge needle fitted with a 1
mL syringe. Lysate (20 µL) was added to a opaque 96-well reader plate, and the luciferase
activity was measured by Luminometer (Centro LB 960, Berthold Technologies).
DENV2 infectivity plaque assay31—BHK-21 cells (5 × 105) were plated one day prior
to treatment in a 12-well plate. Cells were infected with DENV2, and treated with
nucleosides at different concentrations in media containing 1% DMSO for 24 h at 37 °C.
Cell culture supernatant was covered with a first overlayer of media containing 0.9% low-
melting point agarose, 1 × EMEM and 0.5% FBS, and incubated at 37 °C for 6 days. A
second layer containing 0.9% low melting point agarose, 1% NaCl, 0.015% neutral red dye
was added, and the plate was incubated at 37 °C overnight. The number of plaques were
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counted and calculated as PFU/ml. The IC50 values were calculated with a nonlinear four-
parameter curve fit (GraphPad Prism 5.0) of viral titer vs. concentration of nucleoside.
DENV2 infectivity real time PCR assay—The DENV2 RNA copy number was
measured using primers and probe specific to DENV2 NS1 region. The primers and probe
were designed using the Beacon designer 4.0 program. PCR amplification and real-time data
collection and analysis were performed according to iQ5 multicolor real-time PCR detection
system (Bio-Rad). Briefly, a reverse-transcriptase (RT) reaction was carried out using a RT
kit from Bio-Rad (iScript cDNA synthesis). RNA samples (5 µL) were mixed with the
iScript cDNA synthesis mixture and incubated at 42 °C for 30 min. The cDNA product (2
µL) was subjected to PCR using conditions as previously reported.32 Real-time detection of
the DENV2 PCR product was correlated with the input cDNA copy number and the results
were plotted.
Guanidine resistance assay30—Resistance to 2 mM guanidine is conferred by a single
C to U transition mutation in the 2C protein in poliovirus genome. HeLa S3 cells were
plated one day before the experiment at 25% confluence in 10-cm dishes. Cells were
infected with 1 × 106 PFU poliovirus from the appropriate viral stock previously obtained in
the presence or absence of the nucleosides at the concentrations shown in Table S1
(Supporting information). Cells were covered with 20-mL DMEM/F12 media supplemented
with 10% FBS, 1% agarose, 2 mM L-glutamine, 100 U/mL penicillin, 100 U/mL
streptomycin and 2 mM guanidine hydrochloride. The guanidine resistant viral titer (Guar
plaques) was determined.
Nucleotide incorporation by PV RdRP (3Dpol) in vitro—Incorporation of NTPs (8,
9) opposite each of the four templating bases (A, C, G and U) was examined using pre-
assembled 3Dpol-primer/template complexes.36 As previously described, symmetrical
substrate (sym/sub) served as the primer and template RNA. Annealing of 32P-end-labeled
and unlabeled sym/sub oligos to form the primer/template duplex was preformed as
previously described. 3Dpol was allowed to preassemble with sym/sub duplex for 3 min at
30 °C. Incorporation assays with A, C, G and U as templating bases were performed at 30
°C in HEPES buffer (pH 7.5, 50 mM) containing 2-mercaptoethanol (10 mM), MgCl2 (5
mM), 3Dpol (1 µM), sym/sub duplex RNA (0.5 µM) and nucleotide (0.5 mM). All
incorporation assays were initiated by addition of nucleotide, reaction products were
separated by denaturing PAGE, gels were visualized using a phosphorimager, and
radioactivity was quantified using ImageQuant software (Molecular Dynamics).
Measurement of pre-steady state kinetic parameters for 8 and 9 are described in Figure S8
and S9 and references cited therein.
Steady state incorporation assay—Steady-state incorporation of 8 and 9 by PV RdRP
(3Dpol) opposite templating bases U and C was examined. Incorporation of the correct
nucleotide (ATP templated by U and GTP templated by C) and an incorrect nucleotide (GTP
templated by U and ATP templated by C) served as comparative controls. Nucleotide
incorporation reactions contained HEPES buffer (pH 7.5, 50 mM), 2-mercaptoethanol (10
mM), MgCl2 (5 mM), ZnCl2 (60 µM), NTP (1 mM), sym/sub duplex RNA (10 µM) and
3Dpol (1 µM). All incorporation assays were initiated by addition of 3Dpol, and stopped with
50 mM EDTA (final concentration). For steady state assays involving addition of more than
one nucleotide, and where the total nucleotide concentration was greater than 1 mM, the
concentration of MgCl2 was increased to maintain the concentration of free Mg2+ at 4 mM
above the total NTP concentration. The reaction products were separated by denaturing
PAGE, gels were visualized using a phosphorimager, and radioactivity was quantified using
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ImageQuant software (Molecular Dynamics). Data were fit to a linear model using
GraphPad Prism 5.0.
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Panel A: Antiviral effects of compounds against poliovirus. HeLa S3 cells were incubated
with 2–7 for 1 h at the concentrations shown, and subsequently infected with at least 106
PFU of PV. After infection for 15 min, fresh media containing 2–7 was added and the
infection continued for 6 h. Cell-associated virus was titered by plaque assay. Panels B–D:
Cytotoxicity to HeLa S3 cells after treatment with 2–7 for 7 h (B), 24 h (C) or 48 h (D).
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Panel A: Dengue replicon assay. BHK-21 cells expressing DENV2 replicon were treated
with nucleosides for 24 h. After cell lysis, the luciferase signal was measured. Panel B:
Infectivity assay of compound 6 with infectious dengue virus.
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Panels A–E: Incorporation of 8 and 9 into double-stranded RNA by PV RdRP. Complexes
of RNA template and PV RdRP were incubated for 3 min, 8, 9 or the natural NTP (0.5 mM)
was added respectively, and the reaction was allowed to proceed at 30 °C for 1, 5 or 10 min
prior to separation of oligonucleotides by PAGE. In panel E, the percent incorporation
relative to natural NTPs measured from the gel data in A–D is compared.
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Steady state incorporation of 8, 9, ATP or GTP against uracil (panel A) and cytosine (panel
B). 3Dpol (1 µM) was added to the NTP (1 mM) and sym/sub duplex RNA (10 µM) to
initiate the reaction. EDTA was added at 50 mM (final conc.) to stop the reaction at the time
points shown.
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a(a) 1,3-dibromo-5,5-dimethylhydantoin, CH2Cl2; (b) i. HNO3, H2SO4; ii. H2SO4; (c)
SnCl2, HCl; (d) HCOOH; (e) PtO2, Pd/C, NaOH; (f) p-TsOH, β-D-ribofuranose 1,2,3,5-
tetraacetate; (g) NH3, MeOH; (h) Ac2O, pyridine; (i) Pd(PPh3)4, AlMe3, THF; (j) NH3,
MeOH; (k) acetone, p-TsOH, 2,2-dimethoxypropane; (l) NaH, MeCN, MeI; (m) TFA, H2O;
(n) i. PCl3, CH2Cl2; ii. TFA, H2O; (o) TMSCl, pyridine, I2, DMF, (NBu4)3HP2O7.
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Table 2
Kinetic parameters for compounds 8 and 9 as substrates by PV RdRP
Nucleotide kpol (s−1) Kd,app (µM) Efficiency
kpol/Kd,app (s−1·µM−1)
8 11 ± 0.3 170 ± 17 0.06
9 6 ± 0.5 120 ± 36 0.05
ATP42 87 ± 4 134 ± 18 0.65
RTP30 0.014 ± 0.001 496 ± 21 0.00003
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